Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research at NYU Langone Health’s Perlmutter Cancer Center, provides insight on treatment selection for patients with multiple myeloma.
In both the up-front and relapsed/refractory settings, treatment should be selected with the goal of maximizing patient responses, says Morgan.
Patients with heavily pretreated relapsed/refractory multiple myeloma could be considered for the novel XPO1 inhibitor selinexor (Xpovio), which received an accelerated approval from the FDA on July 3, 2019 for use in combination with dexamethasone for the treatment of patients with relapsed/refractory myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Additionally, patients who harbor a translocation(11;14) should be considered for venetoclax (Venclexta), says Morgan.
Finally, enrolling patients on clinical trials remains an option as CAR T-cell therapy and bispecific monoclonal antibodies remain investigational, concludes Morgan.